LIGAND PHARMACEUTICALS INCORPORATED (LGND) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.00% for the 12-month period ending 2015-12-31, per its 10-K filed 2016-11-14.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2016-11-14

• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.00%, a 9.89% increase from fiscal 2014.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2014 was 1.82%, a 0.00% change from fiscal 2013.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.82%, a 59.65% increase from fiscal 2012.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2012 was 1.14%, a 56.32% decline from fiscal 2011.